爵士制药

最新新闻

• 公司公告
  Shanghai Sanyou Medical Co., Ltd: Voluntary Disclosure Notice on the JAZZ System, a spinal fixed connector system, obtained a medical device registration certificate
  SZSI · 2025/7/16
• RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $296
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 公司公告
  Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.
  SEC · 2025/8/12
• 公司公告
  Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)
  SEC · 2024/11/13
• 公司公告
  Jazz Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(9.5%)
  SEC · 2024/10/22
• 公司公告
  Jazz Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cook Jennifer E.
  SEC · 2024/8/7
• 评级变动
  UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $337
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  CCORF Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $271
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $310
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Citi Initiates Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Announces Target Price $325
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Goldman Sachs Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $337
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Announces Target Price $286
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $313
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Form 144 | Jazz Pharmaceuticals(JAZZ.US) Director Proposes to Sell 3.36 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Citi Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $325
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $337
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $283
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $283 to $315
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $281 to $322
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $299
  \u5e02\u573a\u8d44\u8baf · 2026/8/28
• 评级变动
  A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $273 to $307
  \u5e02\u573a\u8d44\u8baf · 2026/8/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。